IGFALS

Across TCGA pan-cancer cohorts, IGFALS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGFALS data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGFALS mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGFALS expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, COAD, and CCRCC are the cancer types where IGFALS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.246	0.722	.004	27	view →
COAD	DFS	Median	II,III,IV	0.880	1.000	.020	24	view →
CCRCC	DFS	Median	All	0.884	0.628	.005	20	view →
GBM	OS	Median	All	0.926	0.611	<.001	17	view →
PDAC	OS	Median	All	0.802	0.890	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IGFALS–LUAD (DFS)

Open the LUAD breakdown →